http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Improving survival after endometrial cancer: the big picture
Janice S.Kwon 대한부인종양학회 2015 Journal of Gynecologic Oncology Vol.26 No.3
To improve survival in women with endometrial cancer, we need to look at the "big picture" beyond initial treatment. Although the majority of women will be diagnosed with early stage disease and are cured with surgery alone, there is a subgroup of women with advanced and high-risk early stage disease whose life expectancy may be prolonged with the addition of chemotherapy. Immunohistochemistry will help to identify those women with Lynch syndrome who will benefit from more frequent colorectal cancer surveillance and genetic counseling. If they happen to be diagnosed with colorectal cancer, this information has an important therapeutic implication. And finally, because the majority of women will survive their diagnosis of endometrial cancer, they remain at risk for breast and colorectal cancer, so these women should be counselled about screening for these cancers. These three interventions will contribute to improving the overall survival of women with endometrial cancer.
Hinkle, Janice L.,Becker, Kyra J.,Kim, Jong S.,Choi-Kwon, Smi,Saban, Karen L.,McNair, Norma,Mead, Gillian E. American Heart Association, Inc. 2017 Stroke Vol.48 No.7
<P>At least half of all stroke survivors experience fatigue; thus, it is a common cause of concern for patients, caregivers, and clinicians after stroke. This scientific statement provides an international perspective on the emerging evidence surrounding the incidence, prevalence, quality of life, and complex pathogenesis of poststroke fatigue. Evidence for pharmacological and nonpharmacological interventions for management are reviewed, as well as the effects of poststroke fatigue on both stroke survivors and caregivers.</P>
Bone health after RRBSO among BRCA1/2 mutation carriers: a population-based study
Helena Abreu do Valle,Paramdeep Kaur,Janice S. Kwon,Rona Cheifetz,Lesa Dawson,Gillian E. Hanley 대한부인종양학회 2022 Journal of Gynecologic Oncology Vol.33 No.4
Objective: Examine the risks of fractures and osteoporosis after risk-reducing bilateral salpingo-oophorectomy (RRBSO) among women with mutations. Methods: In this retrospective population-based study in British Columbia, Canada, between 1996 to 2017, we compared risks of osteoporosis and fractures among women withmutations who underwent RRBSO before the age of 50 (n=329) with two age-matched groups without known mutations: 1) women who underwent bilateral oophorectomy (BO) (n=3,290); 2) women with intact ovaries who had hysterectomy or salpingectomy (n=3,290). Secondary outcomes were: having dual-energy X-ray absorptiometry (DEXA) scan, and bisphosphonates use. Results: The mean age at RRBSO was 42.4 years (range, 26–49) and the median follow-up for women with mutations was 6.9 years (range, 1.1–19.9). There was no increased hazard of fractures for women with mutations (adjusted hazard ratio [aHR]=0.80; 95% confidence interval [CI]=0.56–1.14 compared to women who had BO; aHR=1.02; 95% CI=0.65–1.61 compared to women with intact ovaries). Among women who had DEXA-scan, those with mutations had higher risk of osteoporosis (aHR=1.60; 95% CI=1.00–2.54 compared to women who had BO; aHR=2.49; 95% CI=1.44–4.28 compared to women with intact ovaries). Women with mutations were more likely to get DEXA-scan than either control groups, but only 46% of them were screened. Of the women withmutations diagnosed with osteoporosis, 36% received bisphosphonates. Conclusion: Women with mutations had higher risk of osteoporosis after RRBSO, but were not at increased risk of fractures during our follow-up. Low rates of DEXA-scan and bisphosphonates use indicate we can improve prevention of bone loss.
Glycogen storage disease type Ib neutrophils exhibit impaired cell adhesion and migration
Kim, Goo-Young,Lee, Young Mok,Kwon, Joon Hyun,Jun, Hyun Sik,Chou, Janice Elsevier 2017 Biochemical and biophysical research communication Vol. No.
<P><B>Abstract</B></P> <P>Glycogen storage disease type Ib (GSD-Ib), characterized by impaired glucose homeostasis, neutropenia, and neutrophil dysfunction, is an inherited autosomal recessive disorder caused by a deficiency in the glucose-6-phosphate transporter (G6PT). Neutrophils play an essential role in the defense against invading pathogens. The recruitment of neutrophils towards the inflammation sites in response to inflammatory stimuli is a tightly regulated process involving rolling, adhesion, and transmigration. In this study, we investigated the role of G6PT in neutrophil adhesion and migration using <I>in vivo</I> and <I>in vitro</I> models. We showed that the GSD-Ib (<I>G6pt</I> <SUP>−/−</SUP>) mice manifested severe neutropenia in both blood and bone marrow, and treating <I>G6pt</I> <SUP>−/−</SUP> mice with granulocyte colony-stimulating factor (G-CSF) corrected neutropenia. However, upon thioglycolate challenge, neutrophils from both untreated and G-CSF-treated <I>G6pt</I> <SUP>−/−</SUP>mice exhibited decreased ability to migrate to the peritoneal cavity. <I>In vitro</I> migration and cell adhesion of G6PT-deficient neutrophils were also significantly impaired. Defects in cell migration were not due to enhanced apoptosis or altered fMLP receptor expression. Remarkably, the expression of the β2 integrins CD11a and CD11b, which are critical for cell adhesion, was greatly decreased in G6PT-deficient neutrophils. This study suggests that deficiencies in G6PT cause impairment in neutrophil adhesion and migration via aberrant expression of β2 integrins, and our finding should facilitate the development of novel therapies for GSD-Ib.</P> <P><B>Highlights</B></P> <P> <UL> <LI> GSD-Ib deficient in G6PT is characterized by neutropenia in both blood and bone marrow. </LI> <LI> Neutrophil recruitment into peritoneal cavity is impaired in <I>G6pt</I> <SUP>−/−</SUP> and G-CSF-treated <I>G6pt</I> <SUP>−/−</SUP> mice. </LI> <LI> Neutrophils from <I>G6pt</I> <SUP>−/−</SUP> mice exhibit impaired cell migration and adhesion. </LI> <LI> The aberrant expression of β2 integrins, CD11b and CD11a may lead to impaired cell adhesion in G6pt −/− neutrophils. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma
Sarah Nicole Hamilton,Anna V. Tinker,Janice Kwon,Peter Lim,Iwa Kong,Sona Sihra,Martin Koebel,Cheng Han Lee 대한부인종양학회 2022 Journal of Gynecologic Oncology Vol.33 No.3
Objective: Undifferentiated and dedifferentiated endometrial carcinoma is a rare type of uterine malignancy. This study assesses disease characteristics, treatment and survival outcomes in patients with undifferentiated and dedifferentiated endometrial carcinoma treated at BC Cancer. Methods: All patients diagnosed with undifferentiated and dedifferentiated endometrial carcinoma between 2000 and 2019 at BC Cancer were reviewed centrally. Clinical, pathologic, treatment and outcomes were reviewed retrospectively. The Kaplan-Meier method was used to evaluate overall survival (OS) and disease-free survival (DFS). Multivariable analysis was performed using Cox regression analysis. Results: Fifty-two patients were included, 33% had undifferentiated carcinoma and 67% dedifferentiated carcinoma. Sixty-nine percent of those who had mismatch repair (MMR) testing of their tumor had an abnormal profile. The 5-year DFS was 80% (95% confidence interval [CI]=71%–89%) for stage I/II, 29% (95% CI=28%–40%) for stage III and 10% (95% CI 1%–19%) for stage IV. The 5-year OS was 84% (95% CI=75%–92%) for stage I/II, 38% (95% CI=26%–50%) for stage III and 12% (95% CI=1%–24%) for stage IV. Multivariate analysis showed that receiving adjuvant chemotherapy, adjuvant radiotherapy, lower stage and better Eastern Cooperative Group performance status were associated with improved DFS (p<0.05). Conclusion: Patients with stage I/II undifferentiated and dedifferentiated endometrial carcinoma had excellent survival outcomes, those with stage III/IV had worse outcomes, similar to previously reported. Adjuvant chemotherapy and radiotherapy were associated with improved DFS. MMR testing should be performed for these patients due to the high incidence of abnormal profiles.